Shu Jen Chen

Dr. Shu Jen Chen is the Co-founder and Chief Technology Officer of ACT Genomics Co., Ltd. She has gained in-depth knowledge and experience in cancer biology, drug discovery and development, and bioinformatics for over 20 years.

‍

She joined the National Health Research Institute in 1998 as an Assistant Investigator and established the high-throughput screening program for the institute. Dr. Chen moved to TaiGen Biotechnology in 2001 to serve as the Head of In Vitro Pharmacology. In 2006, she joined Chang Gung University as an Associate Professor at the Department of Biomedical Sciences. Dr. Chen specializes in automated drug screening systems, biological databases and data analysis. She has many years of experience in cancer drug discovery and next-generation sequencing operations. She is also familiar with system integration and database design.

‍

Dr. Shu Jen Chen received her PhD in Biochemistry from Virginia Commonwealth University, completed her postdoctoral training at Baylor College of Medicine and then was a Research Assistant Professor at SUNY Buffalo.